• Users Online: 237
  • Print this page
  • Email this page
Year : 2019  |  Volume : 7  |  Issue : 4  |  Page : 142-144

Chronic migraine: Erenumab, new kid on the block

Department of Pharmacology, GMCH, Amritsar, Punjab, India

Correspondence Address:
Dr. Divya Goel
1154-A, Sector 32, Chandigarh
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/AJIM.AJIM_27_19

Rights and Permissions

Migraine is a primary headache disorder and causes substantial pain and disability. Migraine sufferers could suffer from episodic migraine or chronic migraine. While both of these adversely affect the quality of life, the management of chronic migraine patients poses many challenges, as it mainly relies on preventive treatment. Till now, we have very limited options for preventive management of chronic migraine; recently, new drug erenumab has been approved by the Food and Drug Administration. It has shown very promising results in the management of chronic migraine as it acts by novel mechanism as calcitonin gene-related peptide receptor blocker.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded61    
    Comments [Add]    

Recommend this journal